<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) comprise an increasingly common, poor-risk disease cohort without standard treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>This review describes available treatments and recent advances that may influence the clinical management of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RECENT FINDINGS: Multiple retrospective studies have identified poor-risk cytogenetics, chemotherapy resistance, comorbidities from prior <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and therapy, and persistence of the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> as factors that contribute to poor clinical outcomes of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Recent analyses show that t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> can respond to standard therapy, but responses are less durable </plain></SENT>
<SENT sid="4" pm="."><plain>In most cases, cure is made more likely with allogeneic stem cell transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest that improved survival may result from earlier, low-intensity nontransplant therapy, and aggressive pursuit of reduced-intensity transplant approaches in eligible individuals coupled with posttransplant relapse prevention strategies </plain></SENT>
<SENT sid="6" pm="."><plain>Molecular characterization of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> may aid future clinical management decisions and identify targets for therapy </plain></SENT>
<SENT sid="7" pm="."><plain>SUMMARY: Data emerging from recent t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> studies are shedding light on factors that contribute to disease biology and poor clinical outcomes </plain></SENT>
<SENT sid="8" pm="."><plain>These findings can be used to develop strategies to improve the treatment and survival of patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>